Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors

Abstract Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits the degradation of glucagon-like peptide 1 (GLP-1), and has been approved for the treatment of type 2 diabetes (T2D) in clinic. Previous studies have shown linagliptin improves β cell function using animal models and is...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanqing Zhang, Meifen Wu, Wynn Htun, Emily W. Dong, Franck Mauvais-Jarvis, Vivian A. Fonseca, Hongju Wu
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
R
Q
Online Access:https://doaj.org/article/88d07d8e9add4b2fa9564169da40f93b
Tags: Add Tag
No Tags, Be the first to tag this record!